Junshengtai and Suikun Intelligence Enter Long-Term Strategic Collaboration to Advance AI-Driven Drug Discovery

Recently, HighTide and Silexon jointly announced that they have reached a long-term strategic cooperation agreement based on the principles of complementary advantages and strong alliance.

Both parties will actively pursue strategic cooperation in new drug development by leveraging HighTide’s extensive experience in the research and clinical development of novel therapies for chronic diseases—particularly chronic liver diseases and metabolic disorders—and Silexon AI’s unique advantages in artificial intelligence and machine learning algorithmic tools.

Note: The original text has been abridged.